Skip to main content
Injectable viles.

Cipla debuts generic Lupron Depot

Generic Lupron Depot is indicated for palliative treatment of advanced prostate cancer.

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot.

It is indicated for palliative treatment of advanced prostate cancer.

Leuprolide acetate injection depot contains 22.5 mg of leuprolide acetate for 3-month administration given as a single dose injection.

It is supplied as lyophilized microspheres in a single-dose vial as a kit with a prefilled syringe containing 2 ml 0.8% mannitol solution and an easy-to-use Mixject transfer device for a single dose injection.

[Read more: Cipla receives FDA confirmation for generic Revlimid]

"The launch of leuprolide acetate injection depot reinforces our commitment as an organization to bring high quality and affordable treatments to patients in the United States,” said Arunesh Verma, CEO of Cipla North America. “Enabling access to high-quality treatments is core to our purpose of 'Caring for Life'. This launch aligns with our strategy for growth in the complex product segment."

Lupron Depot had a market value of approximately $197 million for the 12-month period ending September 2022, according to IQVIA.

[Read more: Cipla wins FDA OK for generic Imitrex]

This ad will auto-close in 10 seconds